| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -4.7 | -6.5 |
| EPS (diluted, $ a share) | $-0.17 | $-0.24 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: INMB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Inmune Bio, Inc.: key numbers
- Share price
- $0.9464Close, Nov 16
- Market cap
- $29.3M
- Shares outstanding
- 30.96MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Inmune Bio, Inc.
All →Inmune Bio Capital Raise of $4.5M
INmune Bio Inc. entered into a securities purchase agreement with a single institutional investor for a $4.5 million registered direct offering and concurrent private placement. The company is issuing 3,000,000 shares of common stock at $1.50 per share along with warrants to purchase an additional 3,000,000 shares at an exercise price of $1.65. Proceeds are intended for working capital and general corporate purposes.
- Value
- $4.5M
Inmune Bio Investor Presentation
INmune Bio filed a formal investor presentation deck and announced a Master Services Agreement with Uniphar to establish a commercialization framework for Ebstrocel. The partnership will initially focus on named-patient access in Europe and the MENA region, providing a capital-efficient infrastructure for international distribution. Additionally, the company submitted a pre-Marketing Authorisation Application to the UK MHRA for Ebstrocel.
- Counterparty
- Uniphar Durbin Ireland Limited
Inmune Bio Leadership Change
INmune Bio, Inc. has expanded its Board of Directors to seven members and appointed R. Duane Clark II and James Sapirstein as independent directors. Mr. Clark currently leads Sanofi's U.S. Rare Diseases business, while Mr. Sapirstein is the CEO of Cocrystal Pharma and has extensive experience in biopharma business development and licensing. These appointments are intended to strengthen the company's commercialization planning for Ebstrocel and its strategic partnering capabilities.